Evogene (EVGN) Stock Price
Evogene Price
Over the last 17 years Evogene grew revenue by 23.1% annually, reaching 8.51 M USD. For Evogene, the net margin of -193.7% is up versus -2,247.1% a few years ago. The consensus 12-month price target for Evogene is 1.53 USD, about 268.1% above where the stock trades today. Of 8 analysts, 7 rate the stock a buy — an overall Buy consensus. The stock trades about 7% above its 52-week low.
Evogene stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Evogene over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Evogene stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Evogene's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Evogene Price |
|---|---|
| 9/25/2026 | 0.42 USD |
| 9/23/2026 | 0.45 USD |
| 9/22/2026 | 0.48 USD |
| 9/21/2026 | 0.46 USD |
| 9/18/2026 | 0.47 USD |
| 9/17/2026 | 0.50 USD |
| 9/16/2026 | 0.49 USD |
| 9/15/2026 | 0.53 USD |
| 9/14/2026 | 0.49 USD |
| 9/11/2026 | 0.48 USD |
| 9/10/2026 | 0.48 USD |
| 9/9/2026 | 0.50 USD |
| 9/8/2026 | 0.50 USD |
| 9/4/2026 | 0.54 USD |
| 9/3/2026 | 0.55 USD |
| 9/2/2026 | 0.53 USD |
| 9/1/2026 | 0.52 USD |
| 8/31/2026 | 0.54 USD |
| 8/28/2026 | 0.54 USD |
| 8/27/2026 | 0.54 USD |
| 8/26/2026 | 0.54 USD |
| 8/25/2026 | 0.55 USD |
| 8/24/2026 | 0.55 USD |
| 8/21/2026 | 0.56 USD |
| 8/20/2026 | 0.56 USD |
| 8/19/2026 | 0.60 USD |
| 8/18/2026 | 0.55 USD |
| 8/17/2026 | 0.56 USD |
| 8/14/2026 | 0.60 USD |
| 8/13/2026 | 0.65 USD |
Evogene Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Evogene Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.00 | 6.00 | 3.00 | 1.00 | – | 1.00 | – | 1.00 | 5.00 | 8.00 | 3.00 | 1.00 | 2.00 | 4.00 | 8.00 | 14.00 |
| -21.43 | -45.45 | -50.00 | -66.67 | – | – | – | – | 400.00 | 60.00 | -62.50 | -66.67 | 100.00 | 100.00 | 100.00 | 75.00 |
| 9.09 | -16.67 | -33.33 | 100.00 | – | 100.00 | – | -400.00 | -40.00 | 12.50 | 12.50 | 12.50 | 12.50 | 12.50 | 12.50 | 12.50 |
| 1.00 | -1.00 | -1.00 | 1.00 | 1.00 | 1.00 | -5.00 | -4.00 | -2.00 | 1.00 | 0.38 | 0.13 | 0.25 | 0.50 | 1.00 | 1.75 |
| -17.00 | -21.00 | -21.00 | -19.00 | -21.00 | -24.00 | -30.00 | -30.00 | -26.00 | -21.00 | -2.00 | -12.00 | -5.00 | -3.00 | -2.00 | -1.00 |
| -154.55 | -350.00 | -700.00 | -1,900.00 | – | -2,400.00 | – | -3,000.00 | -520.00 | -262.50 | -66.67 | -1,200.00 | -250.00 | -75.00 | -25.00 | -7.14 |
| -17.00 | -19.00 | -20.00 | -20.00 | -18.00 | -23.00 | -27.00 | -26.00 | -23.00 | -16.00 | -5.00 | -14.00 | -6.00 | -4.00 | -3.00 | -2.00 |
| 21.43 | 11.76 | 5.26 | – | -10.00 | 27.78 | 17.39 | -3.70 | -11.54 | -30.43 | -68.75 | 180.00 | -57.14 | -33.33 | -25.00 | -33.33 |
| 25.38 | 25.44 | 25.67 | 25.75 | 25.75 | 28.16 | 40.43 | 41.21 | 4.57 | 5.70 | 5.70 | 5.70 | 5.70 | 5.70 | 5.70 | 5.70 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Evogene generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Evogene retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Evogene's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Evogene has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Evogene's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Evogene stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Evogene Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Evogene business model & stock analysis
Evogene SWOT Analysis
Strengths
Evogene Ltd has several strengths that contribute to its competitive advantage:
- Strong technological expertise and focus in the fields of biotechnology and genomics.
- Extensive intellectual property portfolio enabling innovation and differentiation.
- Strategic collaborations with industry leaders, enhancing market access and exposure.
- Diversified revenue streams through multiple business segments.
- Established brand reputation and recognition in the biotech industry.
Weaknesses
Evogene Ltd also faces certain weaknesses that can hinder its progress:
- Heavy dependence on a limited number of key customers, which could pose risks if contracts are not renewed.
- Reliance on external funding sources for research and development activities, potentially impacting financial stability.
- Limited geographical presence, primarily focused on specific markets, reducing potential growth opportunities.
- Highly regulated industry, leading to potential delays or obstacles in obtaining necessary approvals.
Opportunities
Evogene Ltd can leverage the following opportunities for future growth:
- Increasing global demand for sustainable agriculture and bio-based solutions.
- Emerging technologies and advancements in genomics, providing new avenues for innovation.
- Growing partnerships and collaborations that can expand market reach and diversify product offerings.
- Expanding into new geographical regions with untapped market potential.
- Government support and incentives for research and development activities in the biotech sector.
Threats
Evogene Ltd must navigate the following threats that could impact its business:
- Intense competition from established players and emerging startups in the biotech industry.
- Economic downturns and market fluctuations that may impact customer spending and demand.
- Stringent regulatory environment, including potential changes in regulations or policies.
- Rapid technological advancements that could render existing products or technologies obsolete.
- Potential disruptions in supply chain and distribution channels due to unforeseen events.
Evogene Segments
Evogene Revenue by Segment
3 Years
5 Years
Max
Details
Evogene Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Evogene historical P/E ratio, EBIT multiple, and P/S ratio
Evogene annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down Evogene's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in Evogene's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare Evogene's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Evogene shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Evogene stock splits
Since 2013, a total of 0.05 shares have been converted from one Evogene share.
Current Evogene forecasts and price targets in September 2026
Analyst Price Targets 2026Evogene Earnings Calls
Evogene Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 11/18/2026 | -0.27USD | - | 400,000.00USD | - | 2026 Q3 |
| 8/18/2026 | -0.27USD | -0.13USD | 325,000.00USD | - | 2026 Q2 |
| 5/20/2026 | -0.27USD | -0.60USD | 350,000.00USD | - | 2026 Q1 |
| 3/5/2026 | -0.26USD | -0.61USD | 275,000.00USD | - | 2025 Q4 |
| 11/20/2025 | -0.26USD | -0.31USD | 275,000.00USD | - | 2025 Q3 |
| 8/19/2025 | -0.63USD | -0.62USD | 930,000.00USD | - | 2025 Q2 |
| 3/6/2025 | -0.72USD | 0.06USD | 5.00 MUSD | - | 2024 Q4 |
| 11/21/2024 | -1.01USD | -1.31USD | 3.63 MUSD | - | 2024 Q3 |
| 8/22/2024 | -0.12USD | -1.06USD | 800,000.00USD | - | 2024 Q2 |
| 5/23/2024 | -0.09USD | -0.80USD | 3.50 MUSD | - | 2024 Q1 |
Evogene shareholder structure
| % | Name |
|---|---|
0.36717% | |
0.24506% | |
0.24185% | |
0.17391% | |
0.17228% | |
0.16192% |
Evogene Executives and Management Board
16 members · avg. age 53 · 13 % women
Mr. Ofer Haviv (56)
President, Chief Executive Officer · since 2002
530,000.00 USD
Management
Dr. Elran Haber (42)
Chief Executive Officer of Biomica Limited
Mr. Mark Kapel (45)
Executive Vice President - Technology
Ms. Dorit Kreiner (50)
Chief Financial Officer
Dr. Arnon Heyman (45)
Chief Executive Officer of Canonic Limited
Dr. Brian Ember (46)
Chief Executive Officer of AgPlenus Limited
Mr. Sassi Masliah (43)
Executive Vice President - Corporate Development
Board of Directors
Mr. Leon Recanati (74)
Independent Director
Mr. Nir Nimrodi
Chairman of the Board · since 2025
Mr. Dan Falk (79)
Independent Director
Ms. Sarit Firon (56)
Independent Director
Mr. Ziv Kop (51)
Independent Director
Dr. Adrian Percy
Independent Director
Frequently asked questions about Evogene
The business model of Evogene Ltd revolves around leveraging advanced biotechnology to develop innovative agricultural solutions. Evogene specializes in computational biology, genomics, and predictive algorithms to accelerate seed and crop improvement processes. Through strategic collaborations with leading seed and agrochemical companies, Evogene aims to provide sustainable and high-performing crop traits that enhance productivity, yield, and quality. By utilizing its proprietary technologies, Evogene strives to address challenges faced by farmers and the agriculture industry, such as improving crop resilience, combating diseases, and increasing nutritional value. Evogene's business model focuses on applying cutting-edge science to drive agricultural innovation and create value for its customers.
Evogene Ltd is primarily active in the fields of agriculture and biotechnology.
The main competitors of Evogene Ltd in the market include companies such as Monsanto Company, Bayer AG, and Syngenta AG. These companies operate in the same biotechnology sector and compete with Evogene in various aspects, including agricultural research and development, genetically modified products, and crop protection solutions. Evogene Ltd faces competition from these major global players as they strive to capture a significant share of the market and deliver innovative solutions for sustainable agriculture.
Evogene Ltd is an Israeli biotechnology company focused on improving crop productivity and sustainability. Established in 2002, Evogene has developed advanced computational genomics technologies to enhance various traits in crops. By leveraging its proprietary computational biology platform, the company identifies and validates novel genes, leading to the development of improved seeds and agrochemical products. Evogene collaborates with leading seed companies and crop protection firms to bring innovative solutions to the market. With a strong emphasis on research and development, Evogene continues to drive advancements in the agricultural sector, aiming to address global food and environmental challenges through cutting-edge technology.
Evogene Ltd has achieved significant milestones in its journey. Over the years, the company has made remarkable progress and accomplishments. Some notable milestones include the successful development and commercialization of innovative agricultural traits and products. Evogene has also established important collaborations and partnerships with leading companies and organizations in the industry. Through its advanced computational biology and predictive biology capabilities, Evogene has consistently delivered cutting-edge solutions and technologies for enhancing crop productivity and agricultural sustainability. These achievements have solidified Evogene's position as a pioneering player in the field, driving growth and value creation for the company and its stakeholders.
Evogene Ltd is primarily present in Israel and has a significant presence in the United States as well.
Evogene Ltd represents values of innovation, sustainability, and collaboration. With a strong corporate philosophy, Evogene is committed to developing cutting-edge technologies in the fields of agroscience and crop improvement. By harnessing the power of computational biology and advanced genomic technologies, Evogene strives to address global challenges in food security and sustainable agriculture. The company focuses on partnerships and collaborations with leading industry players to drive the development and commercialization of its innovative solutions. Through its dedication to scientific excellence and a sustainable future, Evogene Ltd aims to revolutionize the agricultural industry and ensure a more productive and resilient food supply.
Analysts currently set an average price target of 1.53 USD for the Evogene stock (median: 1.53 USD), implying +268.1 % versus the latest price. The consensus is based on 8 analyst ratings.
7 analysts currently rate the Evogene stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Evogene to generate revenue of 1.48 M USD and earnings per share of -2.60 USD.
Converted at the current exchange rate, the Evogene share trades at 0.36 EUR (0.42 USD).
The Evogene share (EVGN) is listed on 2 stock exchanges, including: NASDAQ (EVGN).
Evogene Ltd is a leading company in the agricultural biotechnology industry that specializes in discovering and developing new solutions for the challenges of global agriculture. The business model of Evogene is divided into various divisions that are closely interconnected and form the core of the company's operations. One important division is the genomics technology platform that Evogene uses to create models for plants that can increase their resistance to diseases, pests, and environmental stress. Another important area for Evogene is the development of new products for agriculture based on their genomics technology. Evogene collaborates with leading agricultural corporations to develop seeds and other plant products that are tailored to the specific needs of agriculture. One of Evogene's key products is the Insect Control Trait (ICT), which was developed based on RNA interference. ICT is a revolutionary method for controlling pests that allows targeting and elimination of specific genes in the insect's food system. The company also has a division dedicated to the development of fertilizers and other products aimed at increasing crop yield and quality results. Evogene works with universities and research institutions to develop new methods for soil optimization and plant nutrition. In addition to these various divisions, Evogene also has a strong focus on research and development to ensure constant innovation of the offered products and technologies. The company relies on close collaboration with its customers and partners to meet the specific needs of agriculture. In summary, Evogene's business model is geared towards providing sustainable and innovative solutions for the challenges of global agriculture. With its focus on genomics technology and close collaboration with customers and partners, Evogene is well positioned to continue growing and expanding in this field.
The expected revenue of Evogene is 1.48 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Evogene is -14.82 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Evogene is currently -0.16. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Evogene stock.
The price-to-sales ratio (P/S) of Evogene is currently 1.60. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Evogene stock.
The Eulerpool Quality Score for Evogene is 3/10.
The ISIN of Evogene is IL0011050551. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Evogene is A0Q7UP. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Evogene is EVGN. The ticker symbol is used to trade Evogene shares on the stock exchange.
Evogene paid dividends every year for the past 0 years.
Evogene is assigned to the 'Health' sector.
The dividends of Evogene are distributed in USD.
Evogene stock
Evogene Peer Group
Evogene Ticker
Evogene FIGI
All fundamentals and in-depth analysis of Evogene
Our stock analysis for Evogene stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Evogene. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.